Clinical Trial Update: A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of HFB200603 as a single agent and in combination with tislelizumab in adults with advanced solid tumors, including renal cell carcinoma, melanoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Gastric Cancer
• Melanoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma

Drugs mentioned

• HFB200603
• Tislelizumab (tislelizumab)

Snippet

Sponsor: HiFiBiO Therapeutics | Conditions: Renal Cell Carcinoma, Melanoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING